Company intelligence / Profile preview

Innobiochips

Lille (Loos), Hauts-de-France, Franceinnobiochips.fr ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Innobiochips has developed and commercialized high-resolution multiplex diagnostic solutions for transplantation compatibility, blood transfusion testing, infectious diseases including COVID-19, and microbiome analysis. Their platforms are CE-marked and used globally with over one million tests produced annually. No clinical trial results as the company focuses on diagnostics.

Therapeutic areas: Infectious DiseasesImmunologyHematology
Modalities: Device (diagnostic platform)Multiplex immunoassay (diagnostic technology)
Industry: Protein Biomarker Diagnostics

Drug pipeline

3 assets

Omnys

Commercial

Indications: Blood typing, Blood grouping

2 more assets in the full pipeline.

Request access →

Partnerships

Not specified in public sources as of June2025.

Beyond the preview

Go deeper on Innobiochips.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innobiochips.

Explore the full profile